Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting.

BARCELONA, Spain, September 20, 2024 /PRNewswire/ — Highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress took place from September 13 to 17 to Barcelona, Spain. As one of the most influential annual conferences in oncology, this conference brings together leading cancer experts and researchers from around the world, showcasing the latest developments- rao in the field and provide world-class educational and networking opportunities for oncology professionals.

Biosyngen, a new biotechnology company specializing in stem cell therapy, has demonstrated the basic technology of genetically modified, functionally enhanced tumor-infiltrating lymphocytes (TILs) derived from liver cancer samples.

BioSyngen has received approval for ten clinical trials in China and the US for its fourth-generation oncology treatments. Now, Our first pipeline product, BRG01, is in a pivotal Phase II clinical trial for solid tumors. In addition, the first patients have been enrolled in Phase I trials for our other original treatments, BST02 and. BRL03with the completion of Phase I trials expected later this year.

Article Title

Pre-Clinical Development of Genetically Modified Lymphocytes Using Biopsy Samples from Liver Cancer Patients.

Abstract No.

1034P

Tumor-infiltrating lymphocytes (TILs) are differentiated lymphocytes in the tumor microenvironment that contain T cells capable of recognizing tumor- or virus-associated antigens. In February of this year, the FDA approved the first TIL-based treatment used with IL-2 for advanced metastatic/recurrent melanoma. However, due to the difference in T cell infiltration between hot and cold tumors, different populations of antigen-specific T cells with stronger activation of the immune response of immunity, and the dependence of TIL anti-tumor activity on the simultaneous use of a high concentration of IL-2. treatment, the therapeutic use of unregulated TILs is limited outside of melanoma.

To solve these problems, Biosyngen has developed a proprietary platform for growing TILs from biopsy samples, up to a production of 10.¹¹ cells within four weeks. In addition, the company has developed a sustainable platform for genetic modification that restores TIL metabolism, improves TIL activity and sustainable antitumor activity by introducing membrane anchor proteins. The anti-tumor activity was significantly improved (without IL-2 co-injection) and no obvious toxicity was observed.

Biosyngen has a state-of-the-art TIL product platform aimed at expanding the clinical applications of TIL technology in the following areas:

Automated Production System of TILs: Initiating the use of tumor biopsy samples for TIL preparation with the ability to store tumor cells and end products, overcoming logistical challenges.
Functional In Vitro Gene-engineering System: It uses viral vector technology for stable gene transfer, maintaining high gene activity in TILs.
Development of Extension and In Vivo Persistence: Increased proliferation of central memory T cells (T_CM) final product, leading to long-term persistence.
Antitumor Strengths: It shows potent tumor-killing effects without the need for concomitant use of IL-2.

Source of Biosyngen